Natasha Leighl
Natasha Leighl
Medical Oncology, Princess Margaret
Verified email at
Cited by
Cited by
Pembrolizumab for the treatment of non–small-cell lung cancer
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of Clinical Oncology 36 (17), 1714-1768, 2018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL
M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Journal of Clinical Oncology 27 (8), 1227-1234, 2009
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ...
The Lancet 383 (9930), 1721-1730, 2014
Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update
TJ Smith, K Bohlke, GH Lyman, KR Carson, J Crawford, SJ Cross, ...
Journal of Clinical Oncology 33 (28), 3199-3212, 2015
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ...
Journal of Clinical Oncology 37 (28), 2518, 2019
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III …
M Reck, J Von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Annals of oncology 21 (9), 1804-1809, 2010
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
RG Hagerty, PN Butow, PM Ellis, EA Lobb, SC Pendlebury, N Leighl, ...
Journal of clinical oncology 23 (6), 1278-1288, 2005
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ...
Journal of Clinical Oncology, 2017
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579-583, 2018
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial
DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ...
J Clin Oncol 35 (22), 2490-2498, 2017
Cancer patient preferences for communication of prognosis in the metastatic setting
RG Hagerty, PN Butow, PA Ellis, EA Lobb, S Pendlebury, N Leighl, ...
Journal of clinical oncology 22 (9), 1721-1730, 2004
CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer
T Reungwetwattana, K Nakagawa, BC Cho, M Cobo, EK Cho, A Bertolini, ...
Journal of Clinical Oncology 36 (33), 3290-+, 2018
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
G D'Addario, M Pintilie, NB Leighl, R Feld, T Cerny, FA Shepherd
Journal of clinical oncology 23 (13), 2926-2936, 2005
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ...
Nature genetics 49 (7), 1126-1132, 2017
Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology …
GP Kalemkerian, N Narula, EB Kennedy, WA Biermann, J Donington, ...
Journal of clinical oncology: official journal of the American Society of …, 2018
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials
M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ...
Journal of Clinical oncology 33 (8), 910-915, 2015
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung CancercfDNA Clinical …
NB Leighl, RD Page, VM Raymond, DB Daniel, SG Divers, KL Reckamp, ...
Clinical cancer research 25 (15), 4691-4700, 2019
Perceptions of palliative care among patients with advanced cancer and their caregivers
C Zimmermann, N Swami, M Krzyzanowska, N Leighl, A Rydall, G Rodin, ...
Cmaj 188 (10), E217-E227, 2016
The system can't perform the operation now. Try again later.
Articles 1–20